文献速递药物不良反应与药物警戒

双膦酸盐与皮肤溃疡风险:法国全国队列研究

Use of Bisphosphonates and the Risk of Skin Ulcer: A National Cohort Study Using Data from the French Health Care Claims Database.
PubMed 文献 · Drug Saf · 2023-08-02

基于法国医保数据库2006-2019年代表性样本的队列研究,评估双膦酸盐使用与皮肤溃疡风险。Cox回归显示新暴露者HR 1.40(95%CI 1.26-1.56),但PERR分析HR 1.03(95%CI 0.87-1.24)无显著性,结论为无关联,既往信号可能源于未测量混杂。

要点

  • Cox回归提示双膦酸盐新暴露者皮肤溃疡风险升高(HR 1.40)。
  • PERR分析未发现显著关联(HR 1.03),提示Cox结果可能受混杂影响。
  • 临床应关注双膦酸盐使用者皮肤溃疡风险,但不应据此改变用药决策。

核心结论

  • 在法国人群中未发现双膦酸盐与皮肤溃疡之间存在关联。
  • 既往药物警戒研究和Cox回归分析观察到的关联可能由未测量混杂因素导致。

研究设计与样本

  • 基于法国医保理赔数据库EGB(1/97代表性样本)的种群队列研究,时间跨度2006至2019年。
  • 采用Cox比例风险分析和优先事件率比(PERR)分析,使用两个倾向评分匹配对照组,结局为首次新发溃疡或多事件时间结局。

主要发现

  • 7402名新暴露于双膦酸盐的个体与29605名未暴露个体经倾向评分匹配。
  • 在6911名新暴露者和28072名无既往皮肤溃疡的未暴露者中,Cox回归得出新暴露者的风险比(HR)为1.40(95%CI 1.26-1.56)。
  • 在7402名暴露者和29605名未暴露者中,PERR分析发现非显著HR为1.03(95%CI 0.87-1.24)。
  • 不同敏感性分析结果相似。

临床怎么用

  • 临床处方双膦酸盐时无需因皮肤溃疡风险而改变用药决策。
  • 对使用双膦酸盐的患者,仍应常规关注皮肤溃疡的发生并及时处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Previous pre-clinical and pharmacovigilance disproportionality analyses highlighted a safety signal of cutaneous ulcer with bisphosphonate use. Therefore, our objective is to evaluate this risk and assess whether unmeasured confounding factors could explain this association. METHODS: This study is a population-based cohort study from a representative sample (1/97th) of the French health insurance claims database: Echantillon Généraliste des Bénéficiaires (EGB) from 2006 to 2019. To limit the impact of our study design and methodological choices on any association between skin ulceration and exposure to bisphosphonates, we used several methods: a Cox proportional hazards analysis and a prior event rate ratio (PERR) analysis, using two propensity matched control groups, and either the first episode of incident ulceration or multiple event-time outcomes. RESULTS: There were 7402 individuals newly exposed to bisphosphonates matched to 29,605 unexposed individuals on propensity score. The primary outcome was skin ulcer occurrence assessed by at least 2 deliveries of wound dressing during the period of one month. Among 6911 individuals newly exposed to bisphosphonates and 28,072 unexposed individuals with no previous skin ulcer, the Cox regression yielded a hazard ratio (HR) of 1.40 (95% CI 1.26-1.56) for newly exposed individuals. Among 7402 exposed and 29,605 unexposed individuals, the PERR analysis found a non-significant HR of 1.03 (95% CI 0.87-1.24). Results were similar on the different sensitivity analyses. CONCLUSION: No association between bisphosphonate and skin ulcers was found in the French population. The association observed in previous pharmacovigilance studies and in the Cox regression analysis is likely due to unmeasured confounding factors.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Jambon-Barbara C, Bernardeau C, Bezin J, et al. Use of Bisphosphonates and the Risk of Skin Ulcer: A National Cohort Study Using Data from the French Health Care Claims Database. Drug Saf. 2023. PMID: 37531074. doi:10.1007/s40264-023-01336-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。